Opinion|Videos|March 19, 2025
Personalized Photoprotection Based on Patient Factors
Author(s)Susan Taylor, MD, FAAD
An expert discusses how dermatologists guide patients in selecting sunscreens based on skin type (fair skin, skin of color, sensitive skin), coexisting conditions, and environmental exposure (blue light, heavy sun). They recommend sun protection factor (SPF) levels and key ingredients and address adherence barriers. Beyond sunscreen, protective clothing, antioxidants, and physical blockers help shield against visible light and infrared radiation.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you talk to your patients about choosing an appropriate sunscreen for their skin type and other patient factors?
- Fair skin, skin of color, coexisting skin conditions
- Environments (blue light exposure or heavy sun exposure)
- Choosing appropriate SPF and ingredients
- What factors influence patient adherence to sunscreen use, and how can these challenges be addressed?
- Beyond sunscreen, what additional strategies can be used to protect against visible light and infrared radiation?
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
5